Background
==========

During IVF procedures, a preimplantation genetic diagnosis (PGD) is used to eliminate embryos carrying genetic diseases prior to implantation. The first application of PGD was successfully performed for couples at risk for transmitting recessive X-linked diseases to male offspring \[[@B1]\], whereby polymerase chain reaction (PCR) was used to determine the sex of the embryos.

Unlike PCR methods, preimplantation genetic screening (PGS) aims to provide a means for identifying potentially viable euploid embryos i.e., screening that may improve pregnancy rates. PGS was first described by Verlinsky *et al*. \[[@B2]\] and Munne *et al*. \[[@B3]\]. Although previous methods for embryo screening used fluorescence *in situ* hybridization (FISH) to analyze chromosomes \[[@B4],[@B5]\], the FISH approach is limited because the technique is unable to screen all chromosomes simultaneously. Conventional comparative genomic hybridization (CGH) has been used to comprehensively screen for aneuploidy in oocytes and embryos \[[@B6],[@B7]\]. However, although useful for selecting euploid embryos, the CGH protocol is not generally used because it is time consuming and complicated. At present, both array CGH (aCGH) and single nucleotide polymorphism (SNP) arrays have been validated as accurate methods for producing comprehensive analyses of chromosome in embryos that are compatible with day-3 biopsies and day-5 replacements in a fresh cycle \[[@B8]-[@B12]\]. The difference in mosaicism between embryos at days 3 and 5 has led to a preference for biopsies at the blastocyst stage \[[@B13],[@B14]\].

Here, we describe the results of an embryo analysis and the details of the chromosomal abnormalities found.

Results
=======

In total, we analyzed 150 blastocysts from 49 couples undergoing IVF (Table [1](#T1){ref-type="table"}). Amplification was not detected in 11 (7.3%) embryos, and noisy profile results were obtained for 3.6% (5/139) of the embryos. Euploidy was found in 54.5% of the embryos (73/134), whereas chromosomal abnormalities were found in 45.5% (61/134) of the embryos.

###### 

Array-CGH results

                                   **Number**
  ------------------------------- ------------
  Embryos analyzed                    150
  Euploid embryos                      73
  Aneuploid embryos                    61
  Embryos without amplification        11
  Embryos with noisy profile           5

The details of the array CGH results derived from aneuploid embryos (n=61) are summarized in Table [2](#T2){ref-type="table"}. The type of chromosomal abnormality that was most frequently observed was multiple chromosomal abnormality (34.4%), and the second most frequent was dual chromosomal abnormality (26.2%). Monosomy (21.3%) appeared more frequently than trisomy (18%). Examples of array CGH profiles are shown in Figure [1](#F1){ref-type="fig"}.

###### 

Chromosome abnormality analyzed

  **Aneuploid types**                 **Number (%)**
  ---------------------------------- ----------------
  Single chromosome loss                13 (21.3%)
  Single chromosome gain                11 (18.0%)
  Dual chromosomal abnormality          16 (26.2%)
  Multiple chromosomal abnormality      21 (34.4%)

![**Examples of array CGH results are shown.** (**A**) Array result displaying a female cell with the loss of chromosome 22. (**B**) A male cell with trisomy 21. (**C**) An XY cell showing two chromosomal abnormalities i.e., gain of chromosome 8 and loss of chromosome 14. (**D**) A male cell with multiple chromosomal abnormalities - gain of chromosomes 3 and 15 and loss of chromosome 22. (**E**) A normal female cell. (**F**) A cultured cell with a 2p duplication was used as a positive control.](1755-8166-6-22-1){#F1}

The chromosomes that were most frequently detected to have aneuploidy were, in order, 15, 22, 21, 16, and 18. Chromosomes 4 and 12 were the least frequently found to have aneuploidy.

Discussion
==========

Preimplantation genetic screening for aneuploidy is increasingly used to examine the chromosomes of embryos from couples undergoing IVF \[[@B8]-[@B10],[@B15],[@B16]\]. The purpose of PGS is to identify embryos that are free from chromosomal abnormalities. The main indications for PGS are maternal age, repeated implantation failure, and repeated miscarriage. We examined 150 embryos from 49 couples with these indications.

As shown in Table [1](#T1){ref-type="table"}, we successfully analyzed 89.3% (134/150) of the embryos and found that 45.5% (61/134) of the embryos contained abnormal chromosomes. Although the array CGH method is robust and specific, we observed some failure in amplification and a noisy profile. Some cells containing degraded DNA or samples of low quality resulting from apoptosis can be obtained during the biopsy procedure, causing experimental error.

The results showed excessive single chromosome loss *versus* single chromosome gain (Table [2](#T2){ref-type="table"}); frequent abnormalities in chromosomes 15, 22, 21, 16, and 18; and rare aneuploidy in chromosomes 4 and 12, which are similar to the results of previous reports \[[@B17]-[@B19]\]. Although the frequency of chromosomal abnormalities varied, aneuploidy occurred in all of the 24 chromosomes (data not shown), suggesting that PGS is necessary for selecting healthy embryos during IVF procedures. Previous studies have shown the importance of screening embryos with improved pregnancy success as a result \[[@B19]\].

In conclusion, array CGH is a useful technique for the detection of chromosomal abnormalities during IVF procedures, as previously described \[[@B18]\]. However, embryo cultures up to days 5 or 6 should be established before performing array CGH experiments on blastocysts, and further evidence is required to determine whether PGS results in enhanced delivery rates\[[@B14]\].

Methods
=======

Patient materials
-----------------

A total of 150 blastocysts were collected from 49 couples who visited the clinic center to undergo IVF between September 2011 and December 2012. All patient materials were obtained and evaluated with informed patient consent and under approval from the Ethics Committees of MGMED clinic center and Seoul Rachel Fertility Center. All patients were provided with counseling regarding PGS using array CGH and signed an informed consent prior to entering the study.

Experimental procedures
-----------------------

The biopsied cells were washed in PBS and collected into PCR tubes. Whole-genome amplification was performed using a kit and following the manufacturer's instructions (Sigma-Aldrich, Saint Louis, MO).

Approximately 3 μg of amplified DNA was used in the array CGH experiments, as described, with slight modifications \[[@B20]\]. Briefly, the amplified DNA was labeled with Cy-3 and Cy-5 dCTP for 3 h using a random priming method. The labeled DNA was purified, dissolved in hybridization buffer, and hybridized overnight. The slides were washed several times and dried as described \[[@B21]\]. Images of the slides were acquired with a GenePix4000B dual-laser scanner (Axon Instruments, Union City, CA) and analyzed with MacViewer software \[[@B21]\].
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